FindTrial
Sign In

Does changing every other week (eow)- to every week (ew)-injection of adalimumab influence trough and efficacy in patients with Crohn's disease?-Trough of adalimumab evaluation-TRADE study

Does changing every other week (eow)- to every week (ew)-injection of adalimumab influence trough and efficacy in patients with Crohn's disease?-Trough of adalimumab evaluation-TRADE study - TRADE study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000023735
Enrollment
10
Registered
2016-10-31
Start date
2016-10-31
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

EW or EOW injection of adalimumab

Sponsors

Saitama Medical Center, Saitama Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients with Crohn's disease treated with 80mg EOW adalimumab

Exclusion criteria

Exclusion criteria: Patients with contraindication of adalimumab Pregnant patients and patients with breast-feeding Patients with malignancy or after treatment of malignancy Patients without informed consent Patients determined not to be sufficient for the entry by physicians

Design outcomes

Primary

MeasureTime frame
differences of adalimumab trough level between 80mg EOW- or 40mg EW- injection—

Countries

Japan

Contacts

Public ContactShingo Kato

Saitama Medical Center, Saitama Medical University Department of Gastroenterology and Hepatology

skato@saitama-med.ac.jp049-228-3564

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026